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OBJECTIVES: With the development of next-generation sequencing (NGS) technologies, DNA sequencing has
been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on
treatment decisions for heavily pretreated patients with metastatic cancer.
METHODS:We analyzed metastatic cancer patients from a single institution whose cancers had progressed after
all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis.
We determined the percentage of patients who received any therapy directed by the test, and its efficacy.
RESULTS: From July 2013 to December 2015, 185 consecutive patients were tested using a commercially
available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were
female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test
lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identi-
fied gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result.
Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable
disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time
with matched therapy was 1.6 months, and the median overall survival was 10 months.
CONCLUSION: We identified a high prevalence of gene alterations using an next-generation sequencing test.
Although some benefit was associated with the matched therapy, most of the patients had disease progression
as the best response, indicating the limited biological potential and unclear clinical relevance of this practice.
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’ INTRODUCTION
The enhancement of molecular biology techniques in the
past decades and the subsequent understanding of cell-cycle
control mechanisms have helped to define the hallmarks of
cancer and initiate the era of targeted therapy (1,2). The
development of imatinib for the treatment of patients with
chronic myeloid leukemia has led to an impressive improve-
ment in the clinical management of this disease, initiating a
race to develop and clinically test small-molecule inhibitors
and monoclonal antibodies targeting fundamental effectors
involved in cell carcinogenesis (3,4).
Personalized medicine involves matching the right drugs
to the right patients. The potential benefit of this approach is
very attractive for patients without any remaining conven-
tional therapy available and for whom comprehensive
genomic profiling could identify a potential new, targeted
therapeutic approach. Next-generation sequencing (NGS) is
one of the most advanced technologies applied to decipher-
ing molecular alterations in tumors and enables scientists to
rapidly identify numerous mutations in patient tumors (5-7).
This growing knowledge has significantly improved phar-
maceutical development over the years, leading to some
impressive successes in cancer care (1,2).
One of the first studies to demonstrate the potential benefit
of matched therapy based on molecular profiling in heavily
pretreated patients showed that 98% of the patient tumors
had a gene alteration (GA) that could be used as a target.
That study reported that 27% of the patients had an increase
in progression-free survival (PFS) with treatment based on
tumor molecular alterations compared with the PFS obtained
with their previous treatment (8). Certain other small, retro-
spective studies have also provided evidence of a high
prevalence of GA in patient tumors and suggested the poten-
tial clinical benefit of molecular profiling (9,10); however, the
recent prospective and randomized phase II SHIVA trialDOI: 10.6061/clinics/2017(10)01
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suggested that targeted agents matched according to GAs
outside of their formal indications did not improve PFS (11).
The present retrospective study was conducted to evaluate
the role of genomic testing in treatment decisions for patients
with heavily pretreated metastatic solid tumors at a single
institution.
’ METHODS
Patients
We evaluated consecutive patients with advanced solid
and hematological malignancies, whose tumors were sub-
jected to NGS profiling from July 2013 to December 2015 at
all oncology units of Hospital Sírio-Libanês in São Paulo and
Brasília. Patients 18 years or older who presented with radio-
logical evidence of metastatic disease and failed to respond
or progressed on all recognized standard-of-care therapies
were eligible for analysis. Patients with non-metastatic solid
tumor(s) who did not receive systemic cancer treatment prior
to testing or received targeted therapy based on test results
considered standard for their disease were excluded. Addi-
tionally, outpatients with a loss to follow-up or lack of data
concerning treatment after completing the genomic sequen-
cing via NGS were also excluded.
Clinical characteristics, such as age, gender, the location of
the primary tumor, performance status based on the Eastern
Cooperative Oncology Group (ECOG) score, previous syste-
mic treatment, PFS and overall survival (OS) were obtained
from medical records.
We also compared patients who received targeted therapy
against ERBB2 (HER2) with patients who received targeted
therapy for any other alteration with the exception of HER2.
Analysis of molecular alterations
Patients with adequate tumor tissue from archival formalin-
fixed paraffin-embedded (FFPE) tumor blocks or a minimum
of 10 FFPE slides 4 to 5 mm thick were evaluated using com-
mercially targeted NGS assays (FoundationOne and Founda-
tionOne Heme from Foundation Medicine, Massachusetts,
USA). This test utilizes the DNA sequencing of 315 cancer-
related genes and 28 genes commonly rearranged in cancer.
For hematologic malignancies and sarcomas, the Foundatio-
nOne Heme test was performed, with DNA sequencing for
405 genes somatically altered in cancer and 31 genes involved
in rearrangements in addition to the RNA sequencing of 265
genes. Genomic alterations simultaneously detected by this
assay include base substitutions, short insertions and dele-
tions, focal gene amplifications and homozygous deletions
(copy number alterations), and select gene fusions and
rearrangements (7).
Treatment
A therapy was considered "matched" if a U.S. Food and
Drug Administration (FDA)-approved drug was known to
inhibit the functional activity resulting from at least one of
the GAs of a patient’s tumor, as indicated in the Foundation
Medicine cancer gene panel (FM-CGP) results. The decision
whether to use this matched therapy or not was made by the
patient’s physician.
Objectives and statistical analyses
Our primary objective was to evaluate the response rate of
the tested patients who received therapy directed by NGS-
based genomic profiling. The secondary objectives were to
assess the prevalence of genomic and targetable alterations
and to determine the PFS and OS obtained with the directed
therapies.
All statistical analyses were performed using Predictive
Analytics Software (PASW 18) and R Project for Statistical
Computing. Tumor response was evaluated through com-
puted tomography imaging and retrospectively assessed
using the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 (12). The PFS and OS data were sum-
marized using the Kaplan-Meier method and compared
using the log-rank test. OS was measured from the first day
of treatment with the matched therapy until death or the last
follow-up. PFS was measured from the first day of treatment
until the date of disease progression, death or the last follow-
up, whichever came first. All the P-values presented were
two-sided, and statistical significance was determined when
pp0.05.
This study was approved by the local institutional review
board and was conducted in accordance with state and
federal regulations.
’ RESULTS
Patient characteristics
From July 2013 to December 2015, 185 patients underwent
FM-CGP testing, and 157 patients were eligible for further
analysis. Among the 28 patients excluded from the analysis,
19 patients were lost to follow-up or had no data on treat-
ment after the completion of the genomic sequencing test,
6 patients received targeted therapy considered standard for
the respective histology, and 3 patients were younger than
18 years old.
The baseline characteristics of the 157 patients available for
analysis are described in Table 1. The mean age at diagnosis
Table 1 - Characteristics of the population available for analysis
(N= 157).
Characteristic Number (%)
Women 66 (42.0)
Men 91 (58.0)
ECOG
0 51 (32.5)
1 81 (51.6)
2 16 (10.2)
3 1 (0.6)
Uninformed 8 (5.1)
Mean Age (years) 52.23 years (range 15.3 to 91.25)
Mean prior lines of treatment 2.72 (range 1 to 10)
Tumor Origin
Lung 29 (18.5)
Colorectal 21 (13.4)
Pancreas 17 (10.8)
Soft tissue 11 (7.0)
Stomach 9 (5.7)
Breast 9 (5.7)
Central nervous system 5 (3.2)
Esophagus 5 (3.2)
Liver 5 (3.2)
Unknown primary site 4 (2.5)
Ovary 4 (2.5)
Adrenal 3 (1.9)
Head and neck 3 (1.9)
Gastric-esophageal junction 3 (1.9)
Uterus 3 (1.9)
Others 26 (16.6)
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was 52.2 years (range: 15.3 to 91.2). Sixty-six patients (42.0%)
were female, and ninety-one patients (58.0%) were male.
Most of the patients had an ECOG performance status of 0 or
1 (84.1%). The mean number of treatment lines was 2.7
(range 1 to 10). The most commonly observed tumor sites
were lung (18.5%), colorectal (13.4%) and pancreas (10.8%).
Genomic test results
Among the 185 consecutive patients whose tumors were
analyzed using the FM-CGP, at least one GA was identified
in 177 patients (95.6%). The average number of altered genes
per patient was 3.9 (standard deviation 3.28). Among those
185 patients, 128 patients (69.2%) had at least one targetable
molecular alteration based on an FDA-approved therapy.
Most patients (43.7%) had one, while 25.4% had two or more
druggable alterations.
Treatment and response
Regarding the 157 patients eligible for treatment analysis,
24 patients (15.2%) received systemic treatment directed by
NGS-based genomic profiling testing. Twelve patients (50%)
were male, and twelve patients (50%) were female. The mean
age was 46.8 years. The majority of the patients had an
ECOG performance of 0 or 1 (90.16%). This population was
heavily pre-treated. Most patients (62.6%) had received three
or more previous lines of treatment. The most common pri-
mary sites were lung (12.5%), colorectal (12.5%) and pancreas
(12.5%). The most frequently utilized targeted therapies were
everolimus (25.9%), trastuzumab (11.1%) and T-DM1 (7.4%).
Two patients received more than one line of targeted
therapy based on the FM-CGP results (one patient received
two lines, and the other patient received three lines of
different targeted therapies), with the remaining patients
receiving only one line of matched therapy (Table 2). Among
the patients receiving the 27 different lines of matched
therapy, one patient achieved a complete response (CR), and
four patients achieved a partial response (PR). Three thera-
pies resulted in stable disease (SD), while the best response to
19 therapies was progression of disease (PD) (Table 2). The
overall response rate was 20.8%, and the clinical benefit
(CR+PR+SD) was 29.2%.
The patient who had a CR was a female with adenocarci-
noma of an unknown primary site who had received three
previous lines of systemic therapy. The FM-CGP revealed
a HER2 mutation, and the patient was treated with tras-
tuzumab combined with cisplatin and gemcitabine. After five
months of treatment, CT revealed a complete radiological
response. Four months after the end of the trastuzumab-based
therapy, the patient experienced a radiological progression,
and T-DM1 was initiated, with SD as the best response.
Among the patients with PRs, two patients had metastatic
non-small-cell lung adenocarcinoma (NSCLA) with wild-
type EGFR at diagnosis, which progressed after receiving all
available standard therapies. The NGS-based genomic pro-
filing results revealed a mutation in EGFR, and a PR was
observed with afatinib+cetuximab in one patient and with
afatinib alone in the other patient. The third patient also had
metastatic NSCLA without an EGFR mutation or ALK
Table 2 - Patients treated with targeted therapy based on the results of FoundationOne (N=24).
First-line Treatment Second-line Treatment Third-line Treatment
Primary site Treatment Best Disease
Response
Treatment Best Disease
Response
Treatment Best Disease
Response
Unknown Trastuzumab +
Cisplatin + Gemcitabine
CR TDM-1 SD
Lung Cetuximab + Afatinib PR
Lung Afatinib PR
Lung Crizotinib PR
Breast Everolimus + Exemestane PR
Head and Neck Trastuzumab + Docetaxel SD
Colorectal Cabozantinib +
Panitumumab
SD
Liver Trastuzumab + Docetaxel PD
Soft tissue Everolimus PD
Pancreas Everolimus + Mitomycin +
Cyclophosphamide
PD
Pancreas Everolimus PD
Uterus Everolimus PD
Ovary Everolimus PD
Colorectal T-DM1 PD Trastuzumab + Pertuzumab
+ Capecitabine
PD Lapatinib +
Trastuzumab
PD
Colorectal Sorafenib PD
Pancreas Dasatinib PD
Stomach Trastuzumab +
Carboplatin + Pemetrexed
PD
Breast Everolimus PD
Brain Everolimus PD
Liver Pazopanib PD
Prostate Everolimus PD
Leukemia Nilotinib PD
Gastric-
esophageal
junction
Lapatinib + Paclitaxel PD
Pancreas Palbociclib PD
Abbreviations: CR, complete response; SD stable disease; PR, partial response; PD, progression of disease.
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translocation at diagnosis, which had progressed despite two
different lines of chemotherapy prior to the NGS results. The
test results revealed MET/HGF amplification, and this patient
experienced a PR with crizotinib. The last patient was a female
with metastatic triple-negative breast cancer who had pro-
gressed despite eight lines of prior chemotherapy. The NGS
test results revealed an NF1 gene mutation, and a PR was
observed with everolimus.
The median PFS for patients exposed to matched therapy
was 1.6 months (range, 0.77-10.3 months), and the median
OS was 10 months (range, 0.5-19 months) (Figure 1).
We also evaluated the role of targeted therapy direc-
ted against HER2 alterations and performed a comparison
between these patients and the remaining patients treated
with a matched therapy. A total of 6 patients were treated
with a matched therapy against HER2 alterations, and 19
patients were treated with therapies directed at other targets.
The median PFS was 2 months for patients who underwent
anti-HER2 therapy and 1.5 months for patients who under-
went other targeted therapies (p=0.332). The OS for patients
with anti-HER2 treatment was not reached, and the OS for
those treated with non-HER2 targeted therapies was 9 months
(p=0.866) (Figure 2).
’ DISCUSSION
In this cohort of heavily pretreated patients, we observed
a high prevalence of at least one targetable alteration in
tumor samples (95.6%) with an average of 3.9 mutated
genes per patient. The majority of these molecular alterations
(approximately 70%) were targetable with FDA-approved
therapies. Despite the high prevalence of druggable altera-
tions, only 15% of the patients received a targeted therapy
guided by a specific mutation. Although it was not com-
pletely clear with all patients, the reasons for not being
treated involved patient refusal, treatment cost and no insu-
rance coverage. The outcome analysis revealed a CR in one
patient, a PR in four patients and SD in two patients. The
survival analysis in these patients was not encouraging with
a median PFS of 1.6 months and an OS of 10 months. How-
ever, this population was heavily pretreated and had no
standard treatment available otherwise.
The prevalence of molecular targets and the response rates
observed in our study are consistent with those of other non-
randomized trials. A retrospective study of patients with
cancer of unknown primary site (CUPS), using the same
cancer genome panel as that in our study, found that 96% of
the total cases of CUPS harbored at least one alteration, and
one patient treated with a matched therapy achieved a CR
(10). Similarly, the results of another study indicated that in
patients with at least one targetable alteration, a matched
therapy compared with treatment without matching was
associated with a higher objective response rate (12% vs. 5%;
po0.0001) and a significantly longer PFS (median, 3.9 vs.
2.2 months; p=0.001) and survival (median 11.4 vs. 8.6 months;
p=0.04) (9).
Only a few prospective studies are available in the lite-
rature with conflicting results. A prospective trial presented
at the 2015 American Society of Clinical Oncology (ASCO)
meeting compared the outcomes of patients with advanced
malignancies who were on a molecular alteration-matched
therapy with those on a non-matched therapy. In total, 95%
Figure 1 - A = Progression-free survival for patients with matched therapy based on the results of the FM-CGP.
B = Overall survival for patients with matched therapy based on the results of the FM-CGP.
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of 339 tested patients had at least one GA indicated by NGS.
Patients treated with a matched therapy had significantly
improved PFS (median, 3.9 vs. 3.3 months; p=0.002) and OS
(median, 10.8 vs. 7.5 months; p=0.013) (13). A recent multi-
center, open-label, randomized, controlled phase 2 trial of
molecularly targeted therapy based on tumor molecular
profiling versus treatment based on the physician’s choice in
patients with refractory cancer (the SHIVA trial) revealed no
difference in PFS between the two arms (median, 2.3 vs. 2.0
months, hazard ratio: 0.88, 95% CI 0.65-1.19, p=0.41). The
objective responses also did not differ between the two
groups (4.1% vs. 3.4%, p=0.19). In a subgroup analysis of
patients with alterations in the RAF/MEK pathway, the HR
was 0.58. However, this value was not significant, possibly
due to the small number of patients in the subgroup (11).
The most interesting result in our series was a patient with
an adenocarcinoma of unknown primary site with a HER2
mutation who experienced a CR with trastuzumab-based
therapy. Based on this observation, we compared targeted
therapies against a HER2 alteration with other therapies.
Although clearly exploratory, our data failed to demonstrate
a significant difference between targeted therapies directed
against HER2 versus those directed at other targets.
Comprehensive genomic profiling has the potential to sig-
nificantly change clinical practice by individualizing patient
treatment. For more than two decades, molecular alterations
in tumor cells have been guiding anticancer drug develop-
ment with increasing success (14,15). The recent advent of
NGS technologies has revolutionized the field of human
genetics, enabling the fast and cost-effective generation of
data (16,17). These technologies have potential applications
for many purposes, such as the identification of multiple
GAs that can be targeted in personalized therapy (18).
However, despite the latest progress in this technology, our
study suggests that only a few patients experienced clinical
benefit from targeted therapy based solely on NGS results.
Therefore, many points must be considered regarding the
clinical use of these data. First, as shown in our study, most
tumor samples have more than one targetable GA, and the
prioritization of the choices for targeted therapy taking into
account the different mechanisms of resistance remains a
challenging task (11,19). Second, it is important to emphasize
that not all alterations of the genes involved in carcinogen-
esis will act as ‘‘drivers’’ with the potential to respond to
targeted therapy. In addition, many of the rare oncogene
variants are of uncertain functional and clinical significance
and require further studies (19). The costs associated with
NGS and the difficulty in estimating cost effectiveness are
also complicating factors.
The evolution of genomics knowledge has consistently
demonstrated that solid cancers have extensive heterogene-
ity among individual tumors and among different regions of
the same tumor, which could contribute to treatment failure
and drug resistance (20-22). Therefore, as Marco Gerlinger
has stated, "reconstructing tumor clonal architectures and
the identification of common mutations located in the trunk
of the phylogenetic tree may contribute to more robust
biomarkers and therapeutic approaches" (20).
Matched therapy appears to benefit a few patients whose
cancers have progressed despite all available standard
Figure 2 - A = Progression-free survival for patients with targeted therapy against HER2 versus any other targeted therapy.
B = Overall survival for patients with targeted therapy against HER2 versus any other targeted therapy.
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therapies, and how to identify these patients remains elusive.
Furthermore, as the development of new drugs progresses,
new challenges emerge. In the modern era, immunotherapy
has increasingly demonstrated activity in many tissues;
therefore, we evaluated the mutational load identified by
cancer gene panels, such as the FM-CGP, and the clinical
benefit of a PD-1 blockade in non-small-cell lung cancer
patients. Patients harboring a high mutational load (more
than 7 mutations found in the FM-CGP) had a statistically
significant benefit from anti-PD-1 treatment compared with
the patients with a low mutational load (median PFS of 14.5
vs. 3.4 months, HR: 0.265, p=0.005), suggesting that muta-
tional load could be used as a predictive clinical marker for
immunotherapy (23).
The present study is limited by its retrospective nature, the
small number of patients included, and a possible patient
selection bias. However, our study reflects the outcomes of a
new approach in oncology practice in a distinct selective
population of advanced, heavily treated patients. Our data
are similar to those of other retrospective and non-rando-
mized trials that showed some response in certain indivi-
duals when targeted therapies were used based on the
results of the genomic sequencing of tumor samples; how-
ever, the real benefit remains unclear and is probably smaller
than anticipated.
Future and ongoing trials will add evidence regarding this
matter. The large phase II National Cancer Institute - Mole-
cular Analysis for Therapy Choice (NCI-MATCH) trial will
screen 5,000 patients for a targeted treatment guided by
tumor GAs (24,25). Similarly, the NCI-MPACT (Molecular
Profiling-Based Assignment of Cancer Therapy) trial aims to
compare the response rate and/or 4-month PFS for treatment
with matched therapy guided by molecular aberrations versus
treatment with drugs randomly chosen from a complementary
set of agents (24). MyPathway is an ongoing phase II trial
evaluating four treatment regimens in a population similar
to that in our study, i.e., without available standard treat-
ment. The first analysis of this trial was presented at the
2016 Gastrointestinal Cancer Symposium, and 29 out of
129 patients had some response to targeted therapy, with the
most promising results observed with anti-HER2 therapies in
patients with colorectal, biliary and bladder cancers. The study
is designed to accrue up to 500 patients (26). Similarly, the
TAPUR (Targeted Agent and Profiling Utilization Registry)
study aims to evaluate the role of commercially available
anticancer drugs prescribed for the treatment of patients with
advanced cancer that has a potentially actionable genomic
variant (NCT02693535).
In conclusion, the advancement of cancer genome knowl-
edge associated with the availability of agents that target
altered genes has driven us to consider unusual therapeutic
approaches in patients with an excellent performance status
and without any conventional therapy available. In this sett-
ing, large basket trials will provide knowledge of targetable
mutations in different cancers. Furthermore, hypermutated
tumors could also be suitable candidates for immune check-
point inhibitors, and this possibility should be evaluated in
future clinical trials.
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